An FDA advisory committee's evaluation of Fabre-Kramer Pharmaceuticals Inc.'s investigational antidepressant gepirone may turn on a question of interest to the broader pharmaceutical industry: How should the requirement for substantial evidence of effectiveness be interpreted when there are multiple negative or failed trials along with positive ones?
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?